Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity

Alberto Moreno; Kelly Manning; Maryam I Azeem; Ajay K Nooka; Madison Ellis; Renee Julia Manalo; Jeffrey M Switchenko; Bushra Wali; Jonathan L Kaufman; Craig C Hofmeister; Nisha S Joseph; Sagar Lonial; Kavita M Dhodapkar; Madhav V Dhodapkar; Mehul S Suthar

doi:10.1038/s41541-024-00999-6

Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity

NPJ Vaccines. 2024 Oct 27;9(1):201. doi: 10.1038/s41541-024-00999-6.

Authors

Alberto Moreno^{1

2

3}, Kelly Manning^{1

2}, Maryam I Azeem^{4

5}, Ajay K Nooka^{4

6}, Madison Ellis^{1

2}, Renee Julia Manalo⁴, Jeffrey M Switchenko⁶, Bushra Wali^{1

2}, Jonathan L Kaufman^{4

6}, Craig C Hofmeister^{4

6}, Nisha S Joseph^{4

6}, Sagar Lonial^{4

6}, Kavita M Dhodapkar^{5

6}, Madhav V Dhodapkar^#^{7

8}, Mehul S Suthar^#^{9

10

11}

Affiliations

¹ Emory Vaccine Center, Emory University, Atlanta, Georgia.
² Emory National Primate Research Center, Atlanta, Georgia.
³ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
⁴ Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia.
⁵ Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia.
⁶ Winship Cancer Institute, Atlanta, Georgia.
⁷ Department of Hematology/Medical Oncology, Emory University, Atlanta, Georgia. [email protected].
⁸ Winship Cancer Institute, Atlanta, Georgia. [email protected].
⁹ Emory Vaccine Center, Emory University, Atlanta, Georgia. [email protected].
¹⁰ Emory National Primate Research Center, Atlanta, Georgia. [email protected].
¹¹ Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. [email protected].

^# Contributed equally.

Abstract

Hematological malignancies are associated with an increased risk of complications during SARS-CoV-2 infections. Primary series or monovalent booster vaccines reduce disease severity, hospitalization, and death among multiple myeloma patients. We characterized virus-neutralizing and spike-binding antibody profiles following monovalent (WA1) or bivalent (WA1/BA.5) SARS-CoV-2 booster vaccination in MM patients. Bivalent vaccination improved the breadth of binding antibodies but not neutralization activity against contemporary variants. Hybrid immunity and immune imprinting impact vaccine-elicited immunity.

Abstract

Grants and funding